Cargando…
PB1902: FIRST EUROPEAN REAL-WORLD EVIDENCE PROSPECTIVE REGISTRY OF TAGRAXOFUSP, A CD123-DIRECTED THERAPY, FOR THE TREATMENT OF FIRST-LINE ADULT PATIENTS WITH BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM
Autores principales: | Platzbecker, Uwe, Angelucci, Emanuele, Montesinos, Pau, Lemoni, Roberto M., Spyridonidis, Alexandros, Riggi, Marcello, Zuurman, Michael, Mohty, Mohamad |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429977/ http://dx.doi.org/10.1097/01.HS9.0000974432.10674.cc |
Ejemplares similares
-
Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm
por: Pemmaraju, Naveen, et al.
Publicado: (2022) -
Treatment of leptomeningeal disease in blastic plasmacytoid dendritic cell neoplasm following tagraxofusp-erzs induction
por: Vangala, Deepak B., et al.
Publicado: (2022) -
Foot gangrene following Tagraxofusp treatment for blastic plasmacytoid dendritic cell neoplasm: Case report
por: Sibai, Jad, et al.
Publicado: (2022) -
Tagraxofusp for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Brief Report on Emerging Data
por: Beziat, Guillaume, et al.
Publicado: (2020) -
Tagraxofusp for blastic plasmacytoid dendritic cell neoplasm: a 2-speed cure in the United States and European Union
por: Valentini, Caterina Giovanna, et al.
Publicado: (2023)